Straits Times Index
3,175.19 -12.47 (-0.39%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,245.82 -140.05 (-0.85%) FTSE 100
7,831.21 -45.84 (-0.58%) Bitcoin USD
64,940.65 +4,012.84 (+6.59%) CMC Crypto 200
1,330.87 +18.24 (+1.39%)
Precision BioSciences, Inc. (DTIL)
After hours:
| Previous close | 11.51 |
| Open | 11.41 |
| Bid | 10.69 x 200 |
| Ask | 10.83 x 100 |
| Day's range | 10.71 - 11.66 |
| 52-week range | 8.25 - 27.90 |
| Volume | |
| Avg. volume | 127,183 |
| Market cap | 74.142M |
| Beta (5Y monthly) | 1.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
DURHAM, N.C., April 16, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company. Precision exercised its option to regain rights for the programs following Prevail Therapeutics’ decision to conclude the collaboration. Precision uses its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated g
- Business Wire
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
DURHAM, N.C., March 27, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a business update.
- Business Wire
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
DURHAM, N.C., March 20, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will publish financial results for the fourth quarter and fiscal year 2023 and provide a business update on March 27, 2024.
